Results of a comparison study, presented at ASH 2018, found that salvage HDCT followed by ASCT in patients with relapsed MM did not lead to significant difference in PFS or OS compared with continuous novel agent-based treatment.
A personalized prediction model for probability of survival in patients with MDS who undergo HCT is presented at the ASH 2018 Annual Meeting.
Hemophilic joint bleeding often leads to aberrant expression of alpha-smoot muscle actin, which can indicate vascular remodeling.
Emicizumab prophylaxis provides effective bleed prevention in people with hemophilia A with and without inhibitors.
A novel, von Willebrand factor-independent factor VIII therapy may allow patients with severe hemophilia A to pursue weekly dosing.
The study confirmed that recombinant and plasma-derived FVIII treatment products are associated with similar risk.
Although anovulation is the most common cause of heavy menstrual bleeding, an underlying hemostatic defect may also contribute to this menstrual problem.
The overlapping phenotypes of many hereditary anemias can make differential diagnosis and classification very difficult,
